Limitations of molecularly targeted therapy

Molecularly Targeted Therapy: Imatinib and Beyond

Feasibility of Molecularly Targeted Therapy for Tooth Regeneration

Imatinib Mesylate: A Molecularly Targeted Therapy for Gastrointestinal Stromal Tumors

Although their overall incidence is uncommon, gastrointestinal stromal tumors (GIST) are the most frequently encountered mesenchymal tumors of the GI tract. Their pathology has been recently defined by the presence of KIT (transmembrane receptor tyrosine kinase). The majority of GISTs have c-kit gain-of-function mutations mainly in exon 11 (highly conserved juxtamembrane region) that eventuates...

Molecularly Targeted Therapy for Lung Cancer: Recent Topics

Many clinical trials of molecular target drugs have been done against advanced lung cancer, however, majority did not meet the primary endpoint. Positive studies of EGFR-TKI such as BR21 and Interest used unselected populations of non-small cell lung cancer. It was quite difficult to explain why they were positive. In the present review, the difficulties of clinical trial design in molecular ta...

Guest Editorial Molecularly-Targeted and Biological Anti-Cancer Therapy

The advent of the new millennium was characterized by emergence of dozens of so-called new anti-tumour drugs that differed in many substantial aspects from the established, so far widely used chemotherapy agents. Along with the entrance of these novel anti-tumour agents into clinical practice several new terms and designations came up as well, including molecular targeted therapy, biological th...